StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
OSCRBullishResearch Analysisnews
High materiality8/10

Oscar Health lifts 2026 guidance; analysts raise price targets

Sep 17, 2026, 12:48 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Fresh earnings guidance upgrades and higher price targets indicate durable profitability improvement and potential multiple expansion, especially with strong pre-market momentum and OSCR trading near the 52-week high.

AI summary

What happened, with direct paths to the underlying reporting

Oscar Health raised its 2026 EOP by $100m to $600–$800m, improved MLR to 81.0–82.0%, and reaffirmed revenue guidance of $18.7–$19.0b, triggering fresh price targets from Barclays, Baird and Stephens. OSCR rose about 2.4% in early trading and sits near a 52-week high around $34.47, signaling potential near-term upside.

  • OSCR gains after 2026 guidance upgrade; analysts lift targets.
  • 2026 EOP target raised to $600–$800m; MLR narrowed to 81.0–82.0%.
  • Revenue guidance kept at $18.7–$19.0b; SG&A 15.6–16.1%.
  • Barclays target raised to $49; peers to $33–$34.
  • Stock near 52-week high at $34.47.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event